Sarepta shares rebound after shipments of gene therapy Elevidys resume in US – Reuters

Written by

admin

in

  1. Sarepta shares rebound after shipments of gene therapy Elevidys resume in US  Reuters
  2. Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.  Barron’s
  3. A Quick Look at Today’s Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $10 to $15  富途牛牛
  4. Barclays downgrades Sarepta stock to Underweight on Elevidys concerns  Investing.com
  5. Closing Bell Movers: Sarepta surges as FDA may lift Elevidys shipments pause  TipRanks

Continue Reading

More posts